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This study examined the diagnostic and prognostic value of vascular endothelial growth factor (VEGF) levels in the cerebrospinal fluid
(CSF) of 39 patients with leptomeningeal metastasis (LM). Vascular endothelial growth factor levels at diagnosis were significantly
higher in patients with LM (median 359pgml
 1) than in patients with other neurological diseases (median o25pgml
 1). The
specificity of VEGF levels above 250pgml
 1 for LM was high (98.3%), while the sensitivity was low (51.4%; 73% for VEGF values
above 100pgml
 1). In 49% of the LM patients, particularly with lymphoma or medulloblastoma, VEGF levels were below 250pgml
 1
and thus in the range of VEGF levels in other neurological diseases. Vascular endothelial growth factor levels correlated significantly
with CSF lactate and albumin. Vascular endothelial growth factor levels mirrored the clinical course with a marked reduction in
response to therapy and an increase at relapse in some patients who had serial CSF samples available. Multivariate Cox regression
analysis showed VEGF below 100pgml
 1 (relative risk (RR)¼4.24, P¼0.0002) and age below 60 years (RR¼2.5, P¼0.004) to be
associated with longer survival in LM. In conclusion, CSF VEGF levels in LM vary considerably. High VEGF levels have a very high
specifity for LM and may help to establish the diagnosis. The role of VEGF as a predictor of outcome should be substantiated in
prospective studies.
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The aggressive treatment of leptomeningeal metastasis (LM) with
intrathecal or systemic chemotherapy or radiotherapy should
require the unequivocal demonstration of tumour cell dissemina-
tion within the subarachnoid space. Malignant cells in cerebrosp-
inal fluid (CSF) and contrast-enhancing leptomeningeal lesions on
neuroimaging, suggestive of tumour cell deposits, are regarded
diagnostic of LM. In any other situation suggestive, but not
diagnostic, of LM, additional CSF parameters, would be helpful for
establishing the diagnosis. Ideally, such parameters would not only
be of diagnostic, but also of prognostic value, thus helping to
choose the adequate therapy. Apart from the fact that elevated CSF
protein was almost uniformly found as a negative prognostic
factor, the literature remains controversial on the prognostic value
of low CSF glucose or high CSF lactate levels or high age (Boogerd
et al, 1991; Balm and Hammack, 1996; Fizazi et al, 1996). The many
attempts at defining additional diagnostic or prognostic CSF
parameters for LM have met with little success, mostly because of
low specificity. Vascular endothelial growth factor (VEGF), a
strong inducer of angiogenesis and possibly a cellular survival
factor in many types of cancer, has been evaluated in one
preliminary study: VEGF levels were uniquely high in 11 patients
with LM, while VEGF remained low in patients with non-
neoplastic neurological diseases (Stockhammer et al, 2000). The
present study assesses the differential diagnostic value of CSF
VEGF levels in a substantially larger population with a broader
spectrum of primary tumours. Furthermore, VEGF was investi-
gated as a prognostic parameter in LM, thus extending the scope of
application for the measurement of VEGF in LM.
PATIENTS AND METHODS
A total of 39 patients diagnosed and treated for LM at the
University of Tuebingen Medical Center between 1995 and 2002
were included in this retrospective study. Cerebrospinal fluid
samples from the time of diagnosis of LM, before therapy was
initiated, were available in 37 of these patients. Two additional
patients had multiple samples withdrawn during therapy but no
initial diagnostic sample. Cerebrospinal fluid was routinely drawn
by the lumbar route at diagnosis, whereas follow-up samples,
available in 10 patients, were usually collected from ventricular
reservoirs. In total, 50 patients with non-neoplastic neurological
diseases and normal values for CSF cell count, albumin and lactate,
28 patients with multiple sclerosis, and 37 patients with presumed
infectious CNS disease were included for comparison. The patients
in the latter group were randomly picked from our 2002 and 2003
database if infectious CNS disease was suspected clinically and CSF
cell counts or albumin were abnormal. They presented with clinical
symptoms and signs such as seizures, stiff neck, focal neurological
symptoms including hemiparesis, ataxia, cranial nerve palsies or
(poly)radicular symptoms, and altered mental status. Only one of
these patients had a history of systemic tumour (colon carcinoma).
The 37 patients with suspected infectious disease finally received
the following diagnoses: 11 acute or subacute bacterial meningitis
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lor ventriculitis; six acute (poly)radiculitis, due to borreliosis
(n¼4) or a cause not further specified (n¼2); 12 acute
lymphocytic meningitis or meningoencephalitis, due to varicella
zoster infection (n¼5), tick-borne encephalitis virus (n¼3) or a
cause not further specified (n¼4); three chronic meningitis or
meningoencephalitis, due to presumed tuberculosis (n¼2) or
syphilis (n¼1); five patients were eventually not confirmed to
have infectious CNS disease. In the patients with LM, the diagnosis
was proven by the demonstration of neoplastic cells in the CSF
(49%) or contrast-enhancing subarachnoid tumour cell deposits
on MRI (10%) or both (41%). Survival was recorded in all patients.
Data on systemic tumour control at the time of diagnosis of LM
and the prevalence of subarachnoid contrast-enhancing lesions
were available in 37 out of 39 patients. Information on clinical
response to therapy (improvement, no change, or worsening of
neurological status) as graded by the treating physician was
available for 23 out of 39 patients.
Standard CSF parameters such as cell counts and levels of
albumin, IgG, and lactate were determined at the time of diagnosis
of LM. The presence of malignant cells in CSF was analysed on
cytospin preparations. Cerebrospinal fluid (500ml) was centrifuged
for 4min at 1100r.p.m., and the slides were air-dried, fixed with
acetone and stored until staining at  201C. After Pappenheim
staining, CSF cells were evaluated by cytological criteria. The
origin of malignant cells from particular primary tumours was
further analysed using immunocytochemistry on additional
cytospin preparations. Tumour cells were not quantified. For
VEGF analysis, aliquots of CSF samples were centrifuged
for 10min at 41C and the supernatant was stored at  801C.
Vascular endothelial growth factor levels were determined by
ELISA (R&D Systems, Minneapolis, MN, USA) in duplicate
with 50ml CSF per well and VEGF standard dilutions (15.6–
2000pgml
 1) as provided by the manufacturer. Antibody binding
was visualised by tetramethylbenzidine and hydrogen peroxide
and the colour reaction was measured at 450nm. To correct for
imperfections of the plate, another measurement was carried out at
540nm. The intraassay and interassay variation of this assay was
below 10%. The detection limit of the assay was 25pgml
 1. The
assay recognises both the 121 and 165kDa VEGF isoforms.
According to the manufacturer’s brochure, there are no known
significant interactions of related proteins with the VEGF
measurement. At high concentrations, recombinant human VEGF
receptor 1 (41250pgml
 1) and 2 (410000pgml
 1) and mouse
VEGF receptor 2 (410000pgml
 1) may interfere with the VEGF
assay. The sensitivity, specificity, positive and negative predictive
value and accuracy of VEGF as a marker for LM was estimated
using different cutoff levels. Cerebrospinal fluid VEGF values of
LM patients at diagnosis were correlated with standard
CSF parameters using Pearson product moment correlation.
Differences in CSF parameters between subgroups of patients
were analysed for significance using the Mann–Whitney
U-test. Survival was determined according to Kaplan and Meier
(1958). The association of dichotomised CSF (standard and
VEGF) and clinical parameters (age, gender, presence of sub-
arachnoidal contrast-enhancing lesions on MRI) with survival was
analysed in univariate and multivariate Cox regression analysis.
The course of VEGF levels in response to therapy was followed
in relation to the clinical course in 10 patients with multiple
follow-up CSF samples.
RESULTS
Increased CSF VEGF levels in LM
Initial VEGF values in 37 patients with LM are summarised in
Table 1. The median CSF VEGF concentration was 357pgml
 1 in
the entire group and 569pgml
 1 (range o25 to 43000pgml
 1)i n
patients with systemic primary tumours excluding primary brain
tumours. Vascular endothelial growth factor levels above
250pgml
 1 were frequently found in LM from breast cancer
and melanoma (Table 1). No VEGF was detected in the CSF of
three patients with LM from lymphoreticular tumours.
Vascular endothelial growth factor levels in patients with LM
from primary brain tumours varied. Vascular endothelial
growth factor levels were around 100pgml
 1 in medulloblastoma
Table 1 CSF VEGF levels in 37 patients at the time of diagnosis of LM and in 115 patients with other neurological diseases
N
Median
VEGF value
(pgml
 1)
Minimal
VEGF value
(pgml
 1)
Maximal
VEGF value
(pgml
 1)
Pat.
o100pgml
 1
Pat.
4250pgml
 1
LM (all primary tumours) 37 359 o25 43000 10/37 (27%) 19/37 (51%)
Brain tumours 13 123 o25 43000 4/13 (31%) 5/13 (38%)
8 glioblastoma
2 anaplastic astrocytoma
1 anaplastic
oligodendroglioma
2 medulloblastoma
Lympho-reticular tumours 3 o25 o25 o25 3/3 (100%) 0/3 (0%)
2 CLL
1 Langerhans’ histiocytosis
Melanoma 7 377 o25 43000 2/7 (28%) 5/7 (72%)
Breast cancer 5 1721 o25 43000 1/5 (20%) 4/5 (80%)
Lung cancer 4 497 92 43000 1/4 (25%) 2/4 (50%)
Other solid primary tumours 5 776 130 43000 0 3/5 (60%)
4 CUP
1 ovarian cancer
Other neurological diseases, CSF normal 50 o25 o25 180 48 (96%) 0 (0%)
Multiple sclerosis 28 o25 o25 o25 28 (100%) 0 (0%)
(Suspected) infectious diseases,
pathological CSF
37 o25 o25 2116 31 (84%) 2 (5%)
CLL¼chronic lymphocytic leucaemia; CUP¼cancer of unknown primary; CSF¼cerebrospinal fluid; LM¼leptomeningeal metastasis; VEGF¼vascular endothelial growth
factor.
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lpatients, but were distributed over the whole range of measure-
ments in glioma patients.
Vascular endothelial growth factor levels did not differ between
patients over 60 years (n¼12; median 726pgml
 1) and patients
up to 60 years of age (n¼25; median 146pgml
 1; P¼0.48),
patients with systemic tumour cell deposits at the time of diagnosis
of LM (n¼25; median 377pgml
 1) and patients without (n¼10;
median 174pgml
 1; P¼0.21), or patients with tumour manifesta-
tions in the brain or dura (n¼25; median 377pgml
 1) and
patients without (n¼11; median 241pgml
 1; P¼0.35). Also, there
was no difference in CSF VEGF values between patients with
subarachnoid contrast-enhancing lesions detected by MRI (n¼18;
median 556pgml
 1) and patients without such lesions (n¼18,
median 125pgml
 1, P¼0.32). Further, the VEGF levels of patients
diagnosed by MRI only but not by detection of tumour cells in CSF
(n¼4; median 195pgml
 1) did not significantly differ from the
patients with tumour cells detectable in CSF (n¼33; median
359pgml
 1; P¼0.22). Cerebrospinal fluid VEGF levels were highly
correlated with lactate levels (n¼34; r¼0.79; Po0.00001) and less
so with CSF albumin as a marker for blood–brain barrier
disruption (n¼37; r¼0.54; P¼0.0005), but not with CSF cell
counts (n¼36; r¼0.27; P¼0.16).
Diagnostic value of VEGF in LM
Vascular endothelial growth factor was measured in the CSF of 115
patients with presumed non-neoplastic neurological disease. One
group of 50 patients included patients with normal CSF cell counts,
albumin, IgG, and lactate who had lumbar puncture during
myelography or during diagnostic work-up to exclude inflamma-
tory CNS diseases. Only two of these 50 patients had values slightly
above 100pgml
 1: one patient with symptomatic complex-partial
seizures from a previous stroke and one patient with cerebellar
ataxia of unknown cause. All of 28 MS patients had VEGF levels
below detection limit (25pgml
 1). A third group included 37
patients with pathological CSF due to (suspected) infectious
disease. Six of these patients had VEGF levels above 100pgml
 1:
three patients with VEGF values between 111 and 229pgml
 1 had
ventriculitis, one patient (198pgml
 1) had zoster meningitis, one
patient (441pgml
 1) had a diffuse, nonenhancing swelling of a
cerebellar hemisphere of unknown origin. Infectious causes were
discussed but with a history of active colon cancer a neoplastic
cause could not be ruled out. Another patient had exorbitantly
high levels of VEGF in the CSF (2116pgml
 1). This patient had
axonal polyneuropathy and a suprasellar lesion of unknown
aetiology, but no evidence of LM by MRI or CSF cytology.
Sensitivity, specificity, positive and negative predictive value, and
accuracy for CSF VEGF as a diagnostic marker in LM are
summarised in Table 2. With a cutoff level of 250pgml
 1,
specificity and positive prognostic value were excellent, whereas
sensitivity was low. With a less rigorous cutoff level of 100pgml
 1,
the sensitivity increased (73.7%) while the positive prognostic
value was relatively low (77.8%).
Prognostic value of VEGF in LM
Vascular endothelial growth factor levels at the time of diagnosis of
LM were also evaluated for their prognostic value for a clinical
response to therapy (radiotherapy, chemotherapy, or combined
radiochemotherapy) and overall survival. Pretherapy VEGF values
in eight patients with improvement of neurological status upon
therapy (median 768pgml
 1) were not significantly different from
VEGF levels of 15 patients who did not improve (median
241pgml
 1; P¼0.48). Cerebrospinal fluid cell counts (P¼0.73),
albumin (P¼0.65), IgG (P¼0.94), or lactate (P¼0.31) did not
show significant differences between patients with and without
clinical responses either.
According to a univariate Cox regression analysis (Table 3), a
CSF VEGF level above 100pgml
 1 at diagnosis was a strong
predictor of poor survival. Age over 60 years at diagnosis was a less
potent, but still significant negative predictor of survival. Other
CSF parameters had no prognostic value but due to the small
sample size less potent prognostic factors may have remained
below detection level. Both prognostic factors found in the
univariate analysis were confirmed in the multivariate analysis
(Table 3). The CSF VEGF level was also found as a prognostic
factor (relative risk (RR) 2.51; 95% confidence interval 1.12–10.8,
P¼0.021) when the univariate analysis was restricted to the 24
patients with systemic primary tumours.
Sequential VEGF determinations in the follow-up of LM
patients
A total of 10 patients had sequential CSF samples available for
follow-up VEGF determinations. Eight of these patients had
already VEGF measurement at diagnosis. Two more patients
without initial CSF samples but multiple samples during therapy
were included, one male with adenocarcinoma of the lung and one
female with breast cancer.
The course of six patients with CSF VEGF values changing upon
therapy and relapse is shown in Figure 1. Four additional patients
did not show any change of VEGF levels in multiple CSF samples
and were not included in Figure 1. Two patients (VEGF
o100pgml
 1) received systemic nitrosourea therapy (one mela-
noma, one glioblastoma) and remained neurologically stable; one
patient (VEGF o100pgml
 1) received intrathecal MTX (one
chronic lymphocytic leukaemia). Her neurological status worsened
upon therapy. Vascular endothelial growth factor levels of about
400pgml
 1 remained unchanged during intrathecal MTX therapy
in one patient with melanoma although his neurological status
worsened.
Four of six patients plotted in Figure 1 (one oligodendroglioma,
patient (P) 1; one breast cancer, P3; one melanoma, P4; one lung
cancer P5) were evaluable for the effects of primary intrathecal or
systemic chemotherapy with or without radiotherapy on CSF
VEGF. In all four patients, CSF VEGF levels were substantially
reduced upon therapy and these patients experienced a partial
(n¼2) or complete (n¼2) resolution of clinical symptoms; three
patients were also evaluable for a cytological response: one patient
with oligodendroglioma showed CSF clearance of malignant cells,
in two patients CSF was not cleared. Three of six patients (P1, P2,
P4) were evaluable for CSF VEGF levels upon relapse. In all three
patients, VEGF levels increased substantially. Four of six patients
(P1, P2, P4 P6) were evaluable for response of VEGF levels upon
second-line therapy. Vascular endothelial growth factor levels fell
again in response to (secondary) craniospinal radiotherapy in a
Table 2 Diagnostic value of CSF VEGF levels in patients with LM
Cutoff value Sensitivity (%) Specificity (%) Positive predictive value (%) Negative predictive value (%) Accuracy (%)
100pgml
 1 73 93 77.1 91.5 88.2
250pgml
 1 51.4 98.3 90.5 86.3 86.8
CSF¼cerebrospinal fluid; LM¼leptomeningeal metastasis; VEGF¼vascular endothelial growth factor.
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lpatient with oligodendroglioma. This patient also showed im-
provement of neurological status. In a patient with lung cancer,
second-line intrathecal thiotepa therapy led to a stabilisation of
VEGF values and improvement of neurological status. In two other
patients (one melanoma, one breast cancer), VEGF levels increased
and neurological status declined.
DISCUSSION
The present study demonstrates the diagnostic value of CSF VEGF
determinations in patients with LM. We illustrate the high
specificity of elevated VEGF levels for LM (Table 2), the prognostic
power of initial VEGF values for survival (Table 3) and the possible
use of CSF VEGF as a parameter to monitor response to therapy
(Figure 1). Nevertheless, this study also highlights that neoplastic
and non-neoplastic leptomeningeal disease cannot be safely
distinguished by CSF VEGF and that normal VEGF levels do not
rule out LM.
A preliminary study with 11 LM patients (Stockhammer et al,
2000) had reported that CSF VEGF levels distinguish between
neoplastic and non-neoplastic disease since the ranges of value
obtained in these two groups did not overlap. In the present study
with a substantially larger patient population (n¼37), the
differences in VEGF values between the two groups of patients
were less clearcut. The VEGF values were still highly significantly
different in the two groups, but the ranges overlapped (Table 1).
Some LM patients (20%) had VEGF levels below or close to the
detection limit. The present study included a much broader
spectrum of primary tumours while the previous study comprised
patients with breast, lung, and ovarian cancer only (Stockhammer
et al, 2000). Here also patients with primary brain tumours (e.g.
medulloblastoma), melanoma, lymphoma, and cancer of unknown
primary (CUP) were included. Patients with lymphomas, particu-
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Figure 1 Time course of CSF VEGF levels during the course of disease in
six patients with multiple samples. Patient 1 had oligodendroglioma and
received PCV chemotherapy as first-line therapy and craniospinal radio-
therapy as second-line therapy; patient 2 had adenocarcinoma of the lung,
received intrathecal MTX as first-line and intrathecal thiotepa as second-line
therapy; patient 3 had breast cancer and received intrathecal MTX and
craniospinal radiotherapy; patient 4 had melanoma and received
nitrosourea-based systemic chemotherapy and intrathecal MTX as first-
line and intrathecal AraC as second-line therapy; patient 5 had squamous
carcinoma of the lung and received systemic chemotherapy with etoposide
and carboplatin plus intrathecal MTX therapy; patient 6 had breast cancer
and received intrathecal MTX and whole brain radiotherapy as first-line
therapy and intrathecal thiotepa as second-line therapy.
Table 3 Prognostic factors in patients with LM
Median survival in months (number of patients) Risk ratio (lower–upper 95% CI)
P Condition 1 Condition 2 Condition 2 vs condition 1
Univariate analysis
Age p60 years 460 years
5.8 (26) 1.7 (11) 1.89 (1.13–3.21) 0.02
Gender Female Male
6.8 (19) 2.4 (18) 1.14 (0.74–1.72) 0.58
CSF cell count Normal Elevated
15.9 (12) 4.4 (24) 1.28 (0.80–2.17) 0.31
CSF albumin Normal elevated
NA (7) 3.6 (30) 1.74 (0.93–4.36) 0.08
Subarachnoid contrast-enhancing lesions No Yes
5.6 (19) 4.4 (18) 0.83 (0.52–1.30) 0.42
CSF VEGF p100pgml
 1 4100pgml
 1
NA (10) 2.4 (27) 3.54 (1.6–15.0) 0.0003
Multivariate analysis (n¼36)
Age p60 years 460 years 2.50 (1.34–4.87) 0.004
Gender Female Male 1.61 (0.9–3.1) 0.11
CSF cell count Normal Elevated 0.63 (0.32–1.24) 0.18
CSF albumin Normal Elevated 1.22 (0.56–3.31) 0.63
Subarachnoid contrast-enhancing lesions No Yes 0.85 (0.52–1.41) 0.53
VEGF in CSF p100pgml
 1 4100pgml
 1 4.24 (1.77–18.7) 0.0002
NA¼not assessable; LM¼leptomeningeal metastasis; CSF¼cerebrospinal fluid; VEGF¼vascular endothelial growth factor. Bold values highlight the prognostic factors that
showed significant effects on media survival.
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llarly CLL, or medulloblastomas had low VEGF levels. Even in some
patients with glioblastoma, VEGF levels remained low. There may
possibly be some differences in VEGF levels between LM from
different primaries. However, besides the low VEGF levels in
patients with lymphoreticular tumours, differences in VEGF levels
between different tumour entities were not sufficiently prominent
to be of differential diagnostic relevance. The finding of low VEGF
levels in a proportion of patients with LM greatly reduces the
sensitivity of the assay to detect LM. However, since most cases of
LM can be diagnosed by CSF cytology or MRI, sensitivity is not the
most important feature of a VEGF assay for LM. Specificity is more
important since such an assay may allow to detect high levels of
VEGF in the CSF of patients without diagnostic CSF or MRI
findings. Only two of 115 control cases had VEGF levels above a
cut–off level of 250pgml
 1 (Table 1). Of note, the composition of
the control group influences the figures for specificity and
sensitivity of VEGF in the diagnosis of LM: if the control group
was restricted to patients with presumed infectious disease as the
most appropriate controls, specificity at a cutoff level of
250pgml
 1 would be reduced from 98.3 to 94.5%. Interestingly,
parenchymal CNS metastases are not associated with increased
CSF VEGF levels (Stockhammer et al, 2000) and thus do not impair
the specificity of elevated VEGF levels for LM. Furthermore, the
present study confirms that CSF VEGF levels are low in MS
(Watanabe et al, 1998) and that slightly increased VEGF levels are
found in bacterial meningitis (Stockhammer et al, 2000). Interest-
ingly, one patient with zoster meningitis had slightly increased
VEGF levels.
In contrast to the previous smaller series (Stockhammer et al,
2000), we found a strong correlation of VEGF with CSF lactate and
a less stronger correlation with CSF albumin. The correlation with
CSF lactate makes sense in that lactate may reflect the metabolism
of tumour cells in a low-oxygen environment which in turn
induces VEGF expression in tumour cells (Shweiki et al, 1995;
Fukumura et al, 2001; Ziemer et al, 2001). In fact, acidic pH itself
induces VEGF expression (Fukumura et al, 2001). The possible
value of VEGF as a CSF marker for monitoring LM is reflected by
preliminary data obtained in a small series of patients (Figure 1).
Marked reductions in VEGF levels were accompanied by clinical
improvement in all evaluable patients, whereas increases in VEGF
levels were associated with relapse. Prospective studies will have to
explore in more depth the possibility of monitoring LM by serial
measurements of VEGF. Importantly, VEGF is not only a
diagnostic tool, but may also have prognostic value. Here, VEGF
was a much more potent prognostic factor than CSF albumin.
Further prospective studies have to clarify whether CSF VEGF
levels may serve for risk stratification of patients in studies with
LM. The value of VEGF as a prognostic factor also corresponds to
the fact that increased VEGF is also an independent negative
prognostic factor in systemic tumours and solid brain tumours
(Berkman et al, 1993; Ohta et al, 1996).
Many proteins have been investigated as diagnostic or
prognostic CSF parameters in LM patients during the last 30
years, including carcinoembryonic antigen (CEA; Klee et al, 1986),
lactate dehydrogenase (LDH; Seidenfeld and Marton 1979; Van
Zanten et al, 1986), beta-glucuronidase and beta-microglobulin
(Ongerboer de Visser et al, 1985), a combination of tissue
polypeptide antigen and CK-BB (Bach et al, 1993), fibronectin
(Weller et al, 1990), and the epithelial HMFG-1 antigen (Moseley
et al, 1989). Although most of these parameters are highly sensitive
for LM, their specificity is low because infectious CNS diseases also
showed abnormal CSF findings or this group of patients was not
studied for comparison. In contrast to VEGF (Stockhammer et al,
2000), the CSF levels of some biomarkers are highly influenced by
their serum concentrations or may not allow to differentiate
between leptomeningeal and epidural growth (Klee et al, 1986).
Compared with these previously markers, VEGF appears to offer a
favourable profile of sensitivity and specificity.
In conclusion, this report provides further evidence for the high
specificity of markedly increased levels of CSF VEGF in LM.
However, the relationship between malignant cells in the CSF and
VEGF may be more complex than previously reported (Stock-
hammer et al, 2000) in that the absence of increased CSF VEGF
does not exclude LM. With the strong evidence for VEGF as a
prognostic parameter (Table 3) and the potential ability to follow
LM patients with serial VEGF determinations (Figure 1), VEGF
appears to be an interesting candidate for prospective evaluation
in further clinical studies of LM.
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